NMRD vs. BJDX, SINT, OSAP, MOTS, RSLS, DYNT, INVO, QNRX, TNON, and IONM
Should you be buying Nemaura Medical stock or one of its competitors? The main competitors of Nemaura Medical include Bluejay Diagnostics (BJDX), Sintx Technologies (SINT), ProSomnus (OSAP), Motus GI (MOTS), ReShape Lifesciences (RSLS), Dynatronics (DYNT), INVO Bioscience (INVO), Quoin Pharmaceuticals (QNRX), Tenon Medical (TNON), and Assure (IONM). These companies are all part of the "surgical & medical instruments" industry.
Bluejay Diagnostics (NASDAQ:BJDX) and Nemaura Medical (NASDAQ:NMRD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation.
In the previous week, Bluejay Diagnostics had 2 more articles in the media than Nemaura Medical. MarketBeat recorded 3 mentions for Bluejay Diagnostics and 1 mentions for Nemaura Medical. Nemaura Medical's average media sentiment score of 0.93 beat Bluejay Diagnostics' score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the media.
Nemaura Medical received 2 more outperform votes than Bluejay Diagnostics when rated by MarketBeat users. However, 66.67% of users gave Bluejay Diagnostics an outperform vote while only 57.14% of users gave Nemaura Medical an outperform vote.
Nemaura Medical has a consensus price target of $2.50, indicating a potential upside of 5,455.56%. Given Bluejay Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Nemaura Medical is more favorable than Bluejay Diagnostics.
18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 4.4% of Nemaura Medical shares are held by institutional investors. 17.6% of Bluejay Diagnostics shares are held by company insiders. Comparatively, 41.6% of Nemaura Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Bluejay Diagnostics has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500.
Bluejay Diagnostics' return on equity of 0.00% beat Nemaura Medical's return on equity.
Bluejay Diagnostics has higher revenue and earnings than Nemaura Medical. Nemaura Medical is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
Bluejay Diagnostics beats Nemaura Medical on 9 of the 17 factors compared between the two stocks.
Get Nemaura Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMRD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NMRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nemaura Medical Competitors List
Related Companies and Tools
